Is it safe to administer cabazitaxel to a patient with mCRPC who developed grade 3 pneumonitis from docetaxel?
Are there any precautions or pre-medications that may permit this treatment in patients who are fit for therapy but have exhausted all other treatment options?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Duke University School of Medicine
Answered on
In general, the answer is yes, as these are distinct therapies with distinct toxicities. Both are formulated in TWEEN80 solvent and can cause allergic reactions and anaphylaxis, and this is the only adverse event that I would strongly consider avoiding cabazitaxel if this event was experienced in a ...
Join for free or sign in to see the full answer